H.C. Wainwright analyst Robert Burns raised the firm’s price target on Prelude Therapeutics to $17 from $15 and keeps a Buy rating on the shares following the 2022 results.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- Prelude Therapeutics reports FY22 EPS ($2.44), consensus ($2.47)
- Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
- Prelude Therapeutics, BeiGene enter clinical trial collaboration
- Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences